Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call

10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at...
April 17, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs

CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
April 11, 2019 16:05 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Appoints Joanne Cordeiro to Board of Directors

CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
April 03, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop

CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
March 18, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference

CAMBRIDGE, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
February 25, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results

Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...
February 07, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients

Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modificationEnrollment is complete in the high-dose study arm of Part AExpanded immunologic...
December 20, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate

CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
December 18, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million

CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
December 13, 2018 09:05 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Pricing of $37.5 Million Public Offering

CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...